Number needed to harm and excess cases of Staphylococcus aureus bacteraemia associated with drug exposures
| Treatment exposure | NNH (95% CI) | Excess cases per 10 000 (95% CI) |
| bDMARDs | ||
| User | 1030 (408 to 6695) | 10 (1 to 25) |
| Current user | 1172 (426 to 9374) | 9 (1 to 23) |
| Current TNFi | 937 (335 to 9374) | 11 (1 to 30) |
| Oral glucocorticoids | ||
| User | 665 (334 to 1769) | 15 (6 to 30) |
| Current user | 426 (216 to 1090) | 23 (9 to 46) |
| Cumulative dose (mg) | ||
| ≤1000 | 956 (341 to 9374) | 10 (1 to 29) |
| 1001–1500 | 259 (91 to 1065) | 39 (9 to 110) |
| >1500 | 144 (54 to 451) | 70 (22 to 185) |
| Daily dose (mg) | ||
| ≤7.5 | 781 (312 to 3125) | 13 (3 to 32) |
| >7.5 | 110 (43 to 323) | 91 (31 to 231) |
Risk associated with 1 year of exposure to biological antirheumatic treatment and oral glucocorticoids in Danish patients with rheumatoid arthritis from 2010 to 2018.
All estimates are based on the incidence rate and the fully adjusted ORs from figure 1 if both the OR and the lower confidence limit are above 1 (non-use as reference).
bDMARDs, biological disease-modifying antirheumatic drugs; NNH, number needed to harm; TNFi, tumour necrosis factor alpha inhibitor.